Ginkgo Bioworks vs Amgen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Synthetic biology platform for cell engineering; public company restructuring after SPAC overvaluation, shifting focus to government biosecurity contracts.
About
Ginkgo Bioworks is a synthetic biology platform company that provides cell programming services to the agricultural, pharmaceutical, food, and industrial chemicals industries, helping customers design and manufacture biological products using engineered microorganisms. Founded in 2008 by MIT researchers and headquartered in Boston, Ginkgo went public via SPAC merger in September 2021 at a $15 billion valuation — one of the largest biotech-related SPAC transactions ever.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
About
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.